CelLBxHealth signs master services agreement with AstraZeneca

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell (CTC) intelligence company, has signed a master services agreement with AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical group. The deal establishes CelLBxHealth as a qualified service provider to the Anglo-Swedish giant, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples using its Parsortix platform.